Salim S Hayek1, David E Leaf1, Ayman Samman Tahhan1, Mohamad Raad1, Shreyak Sharma1, Sushrut S Waikar1, Sanja Sever1, Alex Camacho1, Xuexiang Wang1, Ranadheer R Dande1, Nasrien E Ibrahim1, Rebecca M Baron1, Mehmet M Altintas1, Changli Wei1, David Sheikh-Hamad1, Jenny S-C Pan1, Michael W Holliday1, James L Januzzi1, Steven D Weisbord1, Arshed A Quyyumi1, Jochen Reiser1. 1. From the Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor (S.S.H.); the Divisions of Renal Medicine (D.E.L., S. Sharma, S.S.W.) and Pulmonary and Critical Care Medicine (R.M.B.), Brigham and Women's Hospital, the Section of Nephrology, Department of Medicine, Boston University School of Medicine (S.S.W.), and the Divisions of Nephrology (S. Sever) and Cardiology (A.C., N.E.I., J.L.J.), Massachusetts General Hospital - all in Boston; Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta (A.S.T., M.R., A.A.Q.); the Department of Medicine, Rush University Medical Center, Chicago (X.W., R.R.D., M.M.A., C.W., J.R.); the Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston (D.S.-H., J.S.-C.P., M.W.H.); and the Veterans Affairs Pittsburgh Healthcare System and the University of Pittsburgh School of Medicine, Pittsburgh (S.D.W.).
Abstract
BACKGROUND: Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. We investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and we used experimental models to identify mechanisms by which suPAR acts and to assess it as a therapeutic target. METHODS: We measured plasma levels of suPAR preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac surgery and at the time of admission to the intensive care unit in critically ill patients. We assessed the risk of acute kidney injury at 7 days as the primary outcome and acute kidney injury or death at 90 days as a secondary outcome, according to quartile of suPAR level. In experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in transgenic mice receiving contrast material. We also assessed cellular bioenergetics and generation of reactive oxygen species in human kidney proximal tubular (HK-2) cells that were exposed to recombinant suPAR. RESULTS: The suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice. The suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation. Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells. CONCLUSIONS: High suPAR levels were associated with acute kidney injury in various clinical and experimental contexts. (Funded by the National Institutes of Health and others.).
BACKGROUND:Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. We investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and we used experimental models to identify mechanisms by which suPAR acts and to assess it as a therapeutic target. METHODS: We measured plasma levels of suPAR preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac surgery and at the time of admission to the intensive care unit in critically illpatients. We assessed the risk of acute kidney injury at 7 days as the primary outcome and acute kidney injury or death at 90 days as a secondary outcome, according to quartile of suPAR level. In experimental studies, we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in transgenic mice receiving contrast material. We also assessed cellular bioenergetics and generation of reactive oxygen species in human kidney proximal tubular (HK-2) cells that were exposed to recombinant suPAR. RESULTS: The suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice. The suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation. Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells. CONCLUSIONS: High suPAR levels were associated with acute kidney injury in various clinical and experimental contexts. (Funded by the National Institutes of Health and others.).
Authors: Qing Huai; Andrew P Mazar; Alice Kuo; Graham C Parry; David E Shaw; Jennifer Callahan; Yongdong Li; Cai Yuan; Chuanbing Bian; Liqing Chen; Bruce Furie; Barbara C Furie; Douglas B Cines; Mingdong Huang Journal: Science Date: 2006-02-03 Impact factor: 47.728
Authors: Hamid Rabb; Matthew D Griffin; Dianne B McKay; Sundararaman Swaminathan; Peter Pickkers; Mitchell H Rosner; John A Kellum; Claudio Ronco Journal: J Am Soc Nephrol Date: 2015-11-11 Impact factor: 10.121
Authors: Changli Wei; Howard Trachtman; Jing Li; Chuanhui Dong; Aaron L Friedman; Jennifer J Gassman; June L McMahan; Milena Radeva; Karsten M Heil; Agnes Trautmann; Ali Anarat; Sevinc Emre; Gian M Ghiggeri; Fatih Ozaltin; Dieter Haffner; Debbie S Gipson; Frederick Kaskel; Dagmar-Christiane Fischer; Franz Schaefer; Jochen Reiser Journal: J Am Soc Nephrol Date: 2012-11-08 Impact factor: 10.121
Authors: Julie Maja Leth; Katrine Zinck Leth-Espensen; Kristian Kølby Kristensen; Anni Kumari; Anne-Marie Lund Winther; Stephen G Young; Michael Ploug Journal: Int J Mol Sci Date: 2019-06-05 Impact factor: 5.923
Authors: Megan E Kauffman; Melinda K Kauffman; Kassim Traore; Hong Zhu; Michael A Trush; Zhenquan Jia; Y Robert Li Journal: React Oxyg Species (Apex) Date: 2016-09-01
Authors: J Latus; V Schwenger; G Schlieper; H Reinecke; J Hoyer; P B Persson; B A Remppis; F Mahfoud Journal: Internist (Berl) Date: 2020-12-21 Impact factor: 0.743
Authors: A Uzawa; Y Kojima; Y Ozawa; M Yasuda; Y Onishi; H Akamine; N Kawaguchi; K Himuro; S Kuwabara Journal: Clin Exp Immunol Date: 2020-08-10 Impact factor: 4.330
Authors: Alexi Vasbinder; Elizabeth Anderson; Husam Shadid; Hanna Berlin; Michael Pan; Tariq U Azam; Ibrahim Khaleel; Kishan Padalia; Chelsea Meloche; Patrick O'Hayer; Erinleigh Michaud; Tonimarie Catalan; Rafey Feroze; Pennelope Blakely; Christopher Launius; Yiyuan Huang; Lili Zhao; Lynn Ang; Monica Mikhael; Kara Mizokami-Stout; Subramaniam Pennathur; Matthias Kretzler; Sven H Loosen; Athanasios Chalkias; Frank Tacke; Evangelos J Giamarellos-Bourboulis; Jochen Reiser; Jesper Eugen-Olsen; Eva L Feldman; Rodica Pop-Busui; Salim S Hayek; Salim S Hayek; Pennelope Blakely; Hanna Berlin; Tariq U Azam; Husam Shadid; Michael Pan; Patrick O'Hayer; Chelsea Meloche; Rafey Feroze; Kishan J Padalia; Elizabeth Anderson; Danny Perry; Abbas Bitar; Rayan Kaakati; Yiyuan Huang; Lili Zhao; Jochen Reiser; Beata Samelko; Alex Hlepas; Priya P Patel; Xuexiang Wang; Jesper Eugen-Olsen; Izzet Altintas; Marius Stauning; Morten Baltzer Houlind; Mette B Lindstrøm; Hejdi Gamst-Jensen; Line Jee Hartmann; Jan O Nehlin; Thomas Kallemose; Imran Parvaiz; Christian Rasmussen; Ove Andersen; Jens Tingleff; Evangelos J Giamarellos-Bourboulis; Maria-Evangelia Adami; Nicky Solomonidi; Maria Tsilika; Maria Saridaki; Vasileios Lekakis; Sven H Loosen; Tom Luedde; Verena Keitel; Athanasios Chalkias; Eleni Arnaoutoglou; Ioannis Pantazopoulos; Eleni Laou; Konstantina Kolonia; Anargyros Skoulakis; Frank Tacke; Pinkus Tober-Lau; Raphael Mohr; Florian Kurth; Leif Erik Sander; Christoph Jochum Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Peter Pickkers; Michael Darmon; Eric Hoste; Michael Joannidis; Matthieu Legrand; Marlies Ostermann; John R Prowle; Antoine Schneider; Miet Schetz Journal: Intensive Care Med Date: 2021-07-02 Impact factor: 17.440